A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908)

Esophagus

Volumn 2, Issue 3, 2005, Pages 133-137

  Ishikura, Satoshi ^a   Ohtsu, Atsushi ^a   Shirao, Kuniaki ^b   Muro, Kei ^b   Kagami, Yoshikazu ^b   Nihei, Keiji ^a   Mera, Kiyomi ^a   Ito, Yoshinori ^b   Boku, Narikazu ^a   Yoshida, Shigeaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Clinical trial; Drug therapy; Esophageal neoplasms; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; FLUOROURACIL; NEDAPLATIN;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DYSPNEA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS FISTULA; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 25444431754     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-005-0055-3     Document Type: Article

References (23)

1. LR Coia 1994 Chemoradiation as primary management of esophageal cancer Semin Oncol 21 483 92
2. AA Forastiere MB Orringer C Perez-Tamayo SG Urba M Zahurak 1993 Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report J Clin Oncol 11 1118 23
3. A Herskovic K Martz M al-Sarraf L Leichman J Brindle V Vaitkevicius 1992 Combined chemotherapy and radiotherapy in patients with cancer of the esophagus N Engl J Med 326 1593 8
4. M al-Sarraf K Martz A Herskovic L Leichman JS Brindle VK Vaitkevicius 1997 Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study J Clin Oncol 15 277 84
5. A Ohtsu N Boku K Muro K Chin M Muto S Yoshida 1999 Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus J Clin Oncol 17 2915 21
6. S Ishikura K Nihei A Ohtsu N Boku S Hironaka K Mera 2003 Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus J Clin Oncol 21 2697 702
7. MC Christian 1992 The current status of new platinum analogs Semin Oncol 19 720 33
8. DS Alberts PT Fanta KL Running LP Adair Jr DJ Garcia R Liu-Stevens 1997 In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers Cancer Chemother Pharmacol 39 493 7
9. Y Takeda H Kasai N Uchida H Yoshida R Maekawa K Sugita 1999 Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts Anticancer Res 19 4059 64
10. Y Sasaki T Amano M Morita T Shinkai K Eguchi T Tamura 1991 Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion Cancer Res 51 1472 7
11. T Taguchi A Wakui K Nabeya M Kurihara K Isono T Kakegawa 1992 A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group Gan To Kagaku Ryoho 19 483 8 (in Japanese)
12. K Muro N Ando T Nishimaki A Ohtsu K Aogi N Aoyama 2003 A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905 Proc Am Soc Clin Oncol 22 277 (abstract 1112)
13. National Cancer Institute. Common Toxicity Criteria (CTC) version 2.0. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. Accessed December 7, 2004.
14. EL Kaplan P Meier 1958 Non-parametric estimation from incomplete observations J Am Stat Assoc 53 457 81
15. BD Minsky TF Pajak RJ Ginsberg TM Pisansky J Martenson R Komaki 2002 INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy J Clin Oncol 20 1167 74
16. JA Ajani DH Ilson K Daugherty R Pazdur PM Lynch DP Kelsen 1994 Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus J Natl Cancer Inst 86 1086 91
17. EK Rowinsky MJ Citardi DA Noe RC Donehower 1993 Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine J Cancer Res Clin Oncol 119 727 33
18. DH Ilson J Ajani K Bhalla A Forastiere Y Huang P Patel 1998 Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus J Clin Oncol 16 1826 34
19. L Milas Z Fan NH Andratschke KK Ang 2004 Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies Int J Radiat Oncol Biol Phys 58 966 71
20. E Nakata N Hunter K Mason Z Fan KK Ang L Milas 2004 C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy Int J Radiat Oncol Biol Phys 59 1163 73
21. M Baumann M Krause 2004 Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 257 66
22. H Choy L Milas 2003 Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 95 1440 52
23. JA Bonner J Giralt PM Harari R Cohen C Jones RK Sur 2004 Cetuximab (Erbitux TM) prolongs survival in patients with locally advanced squamous cell carcinoma of the head and neck: a phase III study of high dose radiation therapy with and without cetuximab Proc Am Soc Clin Oncol 22 489 (abstract 5507)